Intelligent Bio Solutions Inc. (INBS)
NASDAQ: INBS · Real-Time Price · USD
1.410
+0.020 (1.44%)
At close: Nov 4, 2024, 4:00 PM
1.390
-0.020 (-1.43%)
After-hours: Nov 4, 2024, 7:34 PM EST
Company Description
Intelligent Bio Solutions Inc., a medical technology company, developing rapid, non-invasive testing, and screening solutions.
The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse.
It also operates biosensor platform for clinical chemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.
The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022.
Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York. The company operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Intelligent Bio Solutions Inc.
Country | United States |
Founded | 2016 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 50 |
CEO | Harry Simeonidis |
Contact Details
Address: 135 West, 41ST Street, 5th Floor New York, New York 10036 United States | |
Phone | 646 828 8258 |
Website | ibs.inc |
Stock Details
Ticker Symbol | INBS |
Exchange | NASDAQ |
Fiscal Year | July - June |
Reporting Currency | USD |
CIK Code | 0001725430 |
ISIN Number | US36151G6008 |
Employer ID | 82-1512711 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Harry Simeonidis | President and Chief Executive Officer |
Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law | Chief Financial Officer |
Alex Arzeno | Vice President of Investor Relations |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Oct 29, 2024 | 8-K | Current Report |
Sep 27, 2024 | 8-K | Current Report |
Sep 27, 2024 | 8-K | Current Report |
Sep 19, 2024 | 8-K | Current Report |
Sep 18, 2024 | 8-K | Current Report |
Sep 18, 2024 | 424B5 | Filing |
Sep 18, 2024 | 10-K | Annual Report |
Sep 9, 2024 | 8-K | Current Report |
Sep 5, 2024 | 8-K | Current Report |
Sep 3, 2024 | 8-K | Current Report |